DK1098643T3 - Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme - Google Patents

Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme

Info

Publication number
DK1098643T3
DK1098643T3 DK99932179T DK99932179T DK1098643T3 DK 1098643 T3 DK1098643 T3 DK 1098643T3 DK 99932179 T DK99932179 T DK 99932179T DK 99932179 T DK99932179 T DK 99932179T DK 1098643 T3 DK1098643 T3 DK 1098643T3
Authority
DK
Denmark
Prior art keywords
phenylacetylisoglutamine
phenylacetylglutamine
phenylacetate
pharmaceutical composition
treatment
Prior art date
Application number
DK99932179T
Other languages
Danish (da)
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Application granted granted Critical
Publication of DK1098643T3 publication Critical patent/DK1098643T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
DK99932179T 1998-07-23 1999-07-02 Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme DK1098643T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
DK1098643T3 true DK1098643T3 (da) 2004-05-24

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99932179T DK1098643T3 (da) 1998-07-23 1999-07-02 Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme

Country Status (21)

Country Link
US (2) US6258849B1 (de)
EP (1) EP1098643B1 (de)
JP (2) JP2002521329A (de)
KR (4) KR100417101B1 (de)
CN (3) CN100400039C (de)
AT (1) ATE257378T1 (de)
AU (1) AU759278B2 (de)
BR (1) BR9912356A (de)
CA (1) CA2336945C (de)
DE (1) DE69914084T2 (de)
DK (1) DK1098643T3 (de)
EA (1) EA004179B1 (de)
ES (1) ES2214866T3 (de)
HK (1) HK1037142A1 (de)
ID (1) ID28160A (de)
IL (1) IL140848A (de)
NZ (1) NZ509244A (de)
PL (1) PL213698B1 (de)
PT (1) PT1098643E (de)
WO (1) WO2000004894A2 (de)
ZA (1) ZA200100622B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
TWI249519B (en) * 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
ES2565848T3 (es) 2004-07-07 2016-04-07 Biocon Limited Síntesis de compuestos inmunorreguladores unidos por grupos azoicos
US20060058383A1 (en) * 2004-07-28 2006-03-16 Peng Huang Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents
EP2319581B1 (de) 2004-11-26 2015-02-25 UCL Business PLC Zusammensetzungen enthaltend Ornithin und Phenylacetat oder Phenylbutyrat für die Behandlung von hepatischer Encephalopathie
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
WO2010115055A1 (en) 2009-04-03 2010-10-07 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
EA028395B1 (ru) 2010-10-06 2017-11-30 Осера Терапьютикс, Инк. Способы получения фенилацетата l-орнитина
BR112017010761B1 (pt) 2014-11-24 2022-10-18 Ucl Business Plc Tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
EP3337473A4 (de) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. Behandlung und vorbeugung von muskelschwund durch l-ornithin in kombination mit wenigstens einem phenylacetat und phenylbutyrat
JP6861708B2 (ja) * 2015-12-30 2021-04-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 除脂肪体重を測定するための方法
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
KR20200024145A (ko) 2017-05-11 2020-03-06 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제조방법
WO2018231733A1 (en) * 2017-06-12 2018-12-20 Burzynski Stanislaw R Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472A (zh) * 2022-12-14 2023-07-28 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
DE69914084T2 (de) 2004-10-28
HK1037142A1 (en) 2002-02-01
CN1319010A (zh) 2001-10-24
ES2214866T3 (es) 2004-09-16
CN100400039C (zh) 2008-07-09
US20010044466A1 (en) 2001-11-22
PT1098643E (pt) 2004-05-31
CA2336945A1 (en) 2000-02-03
US6258849B1 (en) 2001-07-10
CN1660061A (zh) 2005-08-31
PL345959A1 (en) 2002-01-14
EA004179B1 (ru) 2004-02-26
EP1098643B1 (de) 2004-01-07
KR100417101B1 (ko) 2004-02-05
AU759278B2 (en) 2003-04-10
WO2000004894A2 (en) 2000-02-03
IL140848A (en) 2005-05-17
KR20030027087A (ko) 2003-04-03
ID28160A (id) 2001-05-10
ZA200100622B (en) 2002-06-26
PL213698B1 (pl) 2013-04-30
NZ509244A (en) 2004-02-27
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
CN1605334A (zh) 2005-04-13
EA200100168A1 (ru) 2001-08-27
JP2011051993A (ja) 2011-03-17
US6943192B2 (en) 2005-09-13
JP2002521329A (ja) 2002-07-16
AU4854299A (en) 2000-02-14
BR9912356A (pt) 2001-04-17
WO2000004894A3 (en) 2000-04-27
KR100417100B1 (ko) 2004-02-05
KR20030027088A (ko) 2003-04-03
EP1098643A2 (de) 2001-05-16
KR20030027089A (ko) 2003-04-03
CA2336945C (en) 2008-11-18
IL140848A0 (en) 2002-02-10
KR100414587B1 (ko) 2004-01-13
ATE257378T1 (de) 2004-01-15
CN1191064C (zh) 2005-03-02
DE69914084D1 (de) 2004-02-12

Similar Documents

Publication Publication Date Title
DK1098643T3 (da) Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
KR960702313A (ko) 티아조푸린 및 리바비린을 사용하는 종양질환의 치료방법 (method for the treatment of neoplastic disease utilizing tlazofurin and ribavirin)
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
NZ510776A (en) Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin
IT1229271B (it) Preparazione medicinale di un estratto delle radici di ortica, urtica kiovensis (rogowicz), suo impiego per il trattamento di tumori e processo di preparazione.
EA199901103A1 (ru) Антивирусный препарат для инъекций
ATE254469T1 (de) Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DK0788355T3 (da) Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme
UA30393A (uk) Спосіб лікування коронарного атеросклерозу
MD2035F1 (en) Method of decreasing the vascular contraction induced by natural vasoconstrictor agents